SCOLR hits “milestone”
This article was originally published in The Tan Sheet
Bellevue, Wash.-based firm SCOLR Pharma announces Sept. 26 that it has achieved a "milestone" in its development and license agreement with Wyeth Consumer Healthcare, which will result in a payment from Wyeth. SCOLR expects to report the payment as "research and development revenues" for the quarter ended Sept. 30. In the original December 2005 agreement, SCOLR granted Wyeth the worldwide rights to utilize SCOLR's patented Controlled Delivery Technology for potential use in an OTC formulations, according to the firm...
You may also be interested in...
SCOLR Pharma will either file an NDA with FDA or work with another pharmaceutical company to develop its 12-hour extended-release ibuprofen product after Wyeth announced it will terminate an agreement with the firm effective April 16
Not all technology platforms provide the expected benefit of filling in CMC review gaps and speeding coronavirus vaccine approvals.
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.